-
Your selected country is
Luxembourg
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Flow cytometric analysis of CD30 expression on YT cell line. YT cells were stained with either PE Mouse Anti-Human CD30 (Cat. No. 550041; solid line histogram) or PE Mouse IgG1, κ Isotype Control (Cat. No. 555749; dashed line histogram). Fluorescent histograms were derived from gated events with the side and forward light-scattering characteristics of viable cells.
BD Pharmingen™ PE Mouse Anti-Human CD30
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Product Notices
- This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
The BerH8 monoclonal antibody specifically binds to CD30, a 120 kDa type I transmembrane glycoprotein expressed on stimulated T and B cells. CD30 is an activation marker initially identified to be expressed on Reed-Sternberg cells. It is also expressed on a few extrafollicular T and B cells located at the rim of germinal centers. CD30 serves as a cytokine receptor. It belongs to the nerve growth factor receptor/tumor necrosis factor receptor (NGFR/TNFR) superfamily and is also known as TNFRSF8. CD30 interaction with CD30 ligand (CD30L/CD153/TNFSF8) can mediate signals for proliferation, apoptosis and cytotoxicity of lymphoid cells.
Development References (6)
-
Beverly PCL. Activation antigens: new and previously defined clusters. In: McMichael AJ. A.J. McMichael .. et al., ed. Leucocyte typing III : white cell differentiation antigens. Oxford New York: Oxford University Press; 1987:516-524.
-
Bowen MA, Olsen KJ, Cheng L, Avila D, Podack ER. Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation. J Immunol. 1993; 151(11):5896-5906. (Biology). View Reference
-
Franke AC, Jung D, Ellis TM. Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies. Hybridoma. 2000; 19(1):43-48. (Biology). View Reference
-
Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:1-1182.
-
Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995.
-
Schwarting R, Stein H. Cluster report CD30. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:419-422.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.